Compare Spotify Technology (SPOT) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spotify Technology vs Viatris Inc — how do they compare? Spotify Technology trades at $492.88 (market cap $101.23B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Spotify Technology is far larger — about 5.1× Viatris Inc's market cap, and Viatris Inc pays a 2.83% dividend while Spotify Technology pays none. Which is the better fit depends on your goals.
| SPOT | VTRS | |
|---|---|---|
Market Cap | $101.23B | $19.79B |
Sector | Media | Health |
52-Week High | $738.53 | $17.39 |
52-Week Low | $412.75 | $8.74 |
Enterprise Value | $91.81B | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Spotify (SPOT) trades at $493.23, up 3.16% today, showing strong momentum with consistent earnings beats in recent quarters. The stock exhibits bullish technical signals with support at $481 and resistance at $500. Fundamentally, revenue grew to $17.19B in 2025 with net income surging to $2.21B, reflecting improved profitability. Recent developments include AI feature expansions and parent-managed accounts for free users, enhancing growth prospects.
Outlook remains positive with analyst consensus target at $617, though rich valuation (P/E 33.54) and competition pose risks. Earnings growth and AI integration present opportunities, but investors should monitor execution against high expectations and market volatility.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
